| Released | Contributor | Author | Title | Pages | Price |
| 10-Feb-2010 | New Constructs, LLC |
N/A
| NEXM: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 9-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 6-Feb-2010 | Pechala's Reports | Frantisek Pechala | NEXMED INC (NEXM=US) 12-months forecast | 1 |
$15 |
| 6-Feb-2010 | Standard & Poor's Quantitative Report |
N/A
| Nexmed Inc | 4 |
$25 |
| 5-Feb-2010 | Pechala's Reports | Lubomir Pechala | NEXMED INC (NEXM=US) 2-weeks forecast | 1 |
$10 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Value Graph: NEXMED -- NEXM | 1 |
$4 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACUS , CORT , ELTP , NEXM , PRWP , RGN , SIGA , SYNI -- DRUGS | 3 |
$4 |
| 31-Jan-2010 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for NexMed, Inc. | 43 |
$65 |
1.52% Nasdaq 0.00%
Research Reports
